Skip to content ↓

MIT releases 2010 endowment figures

Press Contact:

Patti Richards
Phone: 617-253-2700
MIT News Office

Media Download

MIT seal
Download Image

*Terms of Use:

Images for download on the MIT News office website are made available to non-commercial entities, press and the general public under a Creative Commons Attribution Non-Commercial No Derivatives license. You may not alter the images provided, other than to crop them to size. A credit line must be used when reproducing images; if one is not provided below, credit the images to "MIT."

Close
MIT seal

The Massachusetts Institute of Technology Investment Management Company (MITIMCo) announced today that MIT's endowment generated an investment gain of 10.2 percent during the fiscal year ending June 30, 2010.

At the start of Fiscal Year 2010, the value of the endowment was $7.9 billion. Over the course of the year, the endowment received $104 million in new gifts and transfers, and spending from the endowment totaled about $460 million. Factoring in investment gains of $800 million, the market value of the endowment — excluding pledges for endowed purposes — totaled $8.3 billion at the end of the fiscal year. 

MITIMCo’s investment policy is focused on the primary goal of generating high real rates of return without exceptional volatility. The portfolio is primarily invested in equities and heavily weighted toward markets such as private equity, real estate and marketable alternatives. For the past five years, MIT’s endowment has earned an annualized return of 7.2 percent.

MITIMCo is a division of the Massachusetts Institute of Technology, created to manage and oversee the investment of the Institute's endowment, retirement plans and operating funds. As of June 30, 2010, MITIMCo had more than $12 billion of total assets under management.

Related Links

Related Topics

More MIT News

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story